ASC antibody treatment in SH-SY5Y-APP695 cells

Exploratory Score: 0.900 Price: $0.50 Alzheimer's disease SH-SY5Y-APP695 cells Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting ASC in SH-SY5Y-APP695 cells. Primary outcome: Cell apoptosis and Aβ production levels

Description

This experiment investigated the effects of ASC neutralizing antibodies targeting different domains of the ASC protein on cell apoptosis and amyloid-β (Aβ) production in vitro. SH-SY5Y-APP695 cells, which are human neuroblastoma cells transfected to overexpress APP695, were treated with either anti-ASC N-terminal antibodies (targeting the pyrin domain) or anti-ASC C-terminal antibodies (targeting the caspase recruitment domain). The study measured cell apoptosis, mitochondrial damage, and Aβ production levels to assess the differential roles of the two ASC domains in Alzheimer's disease pathogenesis. The mechanism of action was explored by examining BACE1 inhibition, as BACE1 is a key enzyme in Aβ production. Results showed that both antibody treatments reduced apoptosis, mitochondrial damage, and Aβ production through BACE1 inhibition.

TARGET GENE
ASC
MODEL SYSTEM
SH-SY5Y-APP695 cells
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
ASC-mediated inflammasome pathway, amyloid processing pathway
SOURCE
extracted_from_pmid_41707905
PRIMARY OUTCOME
Cell apoptosis and Aβ production levels

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

ASC (PYCARD)genebace1-inhibitors-alzheimerstherapeuticBACE1 ProteinproteinBeta-Secretase (BACE1) ProteinproteinBACE1 Amyloidogenic Cleavage PathwaymechanismBACE1 (Beta-Secretase 1)geneBACE1 (Redirect)redirectTreatmentsindexAlzheimer's Disease PathogenesismechanismMitochondriaentityTREM2 Variants in Alzheimer's DiseasediseaseSporadic vs Familial Alzheimer's Disease: ComprehediseasePSEN2 Mutations in Alzheimer's DiseasediseasePSEN1 Mutations in Alzheimer's DiseasediseaseProdromal Alzheimer's Diseasedisease

Protocol

Treatment of SH-SY5Y-APP695 cells with anti-ASC N-terminal or C-terminal neutralizing antibodies, followed by assessment of cell apoptosis, mitochondrial damage, and Aβ production via BACE1 activity measurement

Expected Outcomes

Reduced cell apoptosis and decreased Aβ production following ASC antibody treatment

Success Criteria

Significant reduction in apoptosis markers, mitochondrial damage, and Aβ levels compared to control

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.